Nuvation Bio Inc.
General ticker "NUVB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $871.7M (TTM average)
Nuvation Bio Inc. follows the US Stock Market performance with the rate: 46.4%.
Estimated limits based on current volatility of 3.8%: low 5.93$, high 6.49$
Factors to consider:
- Total employees count: 220 as of 2024
- China accounted for 66.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Integration challenges, Labor/talent shortage/retention, Economic downturns and volatility, Cybersecurity threats
- Current price 57.9% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.97$, 4.53$]
- 2025-12-31 to 2026-12-31 estimated range: [1.54$, 3.70$]
Financial Metrics affecting the NUVB estimates:
- Positive: with PPE of -5.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.95 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -58.54 <= -0.76
- Positive: Interest expense per share per price, % of 0.05 <= 0.74
- Positive: Shareholder equity ratio, % of 85.79 > 64.17
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.21 <= 0
Short-term NUVB quotes
Long-term NUVB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $7.87MM |
| Operating Expenses | $119.73MM | $99.82MM | $600.50MM |
| Operating Income | $-119.73MM | $-99.82MM | $-592.63MM |
| Non-Operating Income | $15.54MM | $24.02MM | $24.69MM |
| Interest Expense | $0.00MM | $0.00MM | $0.34MM |
| R&D Expense | $87.81MM | $71.29MM | $524.19MM |
| Income(Loss) | $-104.20MM | $-75.80MM | $-567.94MM |
| Profit(Loss)* | $-104.20MM | $-75.80MM | $-567.94MM |
| Stockholders Equity | $655.08MM | $605.12MM | $463.79MM |
| Assets | $672.14MM | $621.48MM | $540.63MM |
| Operating Cash Flow | $-96.11MM | $-68.00MM | $-130.41MM |
| Capital expenditure | $0.37MM | $0.07MM | $0.16MM |
| Investing Cash Flow | $63.46MM | $8.92MM | $122.70MM |
| Financing Cash Flow | $1.33MM | $0.63MM | $0.33MM |
| Earnings Per Share** | $-0.48 | $-0.35 | $-2.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.